Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
Noosa News19 hours agoComing Soon: The Malibu Barbie Cafe Is Popping Up in Australia for the First Time, Complete with a Cocktail-Slinging Ken-Themed Bar
-
Noosa News18 hours agoThe Latest Trailer for ‘Squid Game’ Season Three Is Here — and “No Matter How You Look at It, Life Is Just Unfair”
-
Business14 hours agoHow many Magnificent 7 stocks should I own?
-
General8 hours agoWA government rolls out suite of housing assistance ahead of state budget